Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
To date, clinical data have been reported for two dual GIP/GLP-1 receptor agonists
Whilst these medications do not selectively 'burn' belly fat through direct mechanisms, clinical evidence demonstrates they promote significant overall weight loss, including reductions in visceral adipose tissuethe metabolically harmful fat surrounding internal organs
Stock Patch + Private Label Options The GLP-1 Support Patch is available as a stock transdermal patch, allowing brands to move quickly while still customizing the final product
Pancreatitis Risks Researchers have not determined whether GLP-1 agonists cause pancreatitis or increase the risk of pancreatic cancer, but some users report experiencing acute pancreatitis, including hemorrhagic and necrotizing forms (15)(52)
US$ 26.86
US$ 20.27
US$ 21.95
US$ 21.09
US$ 25.15
US$ 27.96
